The following is a summary of “Evaluation of the relationship between Ki67 expression level and neoadjuvant treatment response and prognosis in breast cancer based on the Neo-Bioscore staging system,” published in the October 2023 issue of Oncology by Sullu et al.
Neoadjuvant chemotherapy (NAC) treats breast cancer, and Ki67, a proliferation marker, can predict response and prognosis. Researchers performed a retrospective study to assess the prognostic importance of the Neo-Bioscore stage and Ki67 before and after NAC and their correlations.
The study included 176 patients with invasive breast carcinoma who received NAC. Using immunohistochemical methods, ki67 levels were assessed in both Trucut biopsy and surgical excision samples. Patients were categorized into prognostic groups based on the Neo-Bioscore staging system.
Patients with high pretreatment Ki67 scores were likelier in the higher Neo-Bioscore risk group (P< 0.001). Those with high posttreatment Ki67 scores were also more likely to fall into the higher Neo-Bioscore prognostic risk group (P< 0.001). In cases of high posttreatment Ki67 scores and patients in the higher Neo-Bioscore risk group, disease-free survival (DFS) and overall survival (OS) were shorter. A cutoff of 37% for the pathological complete response (PCR) was determined.
The study found posttreatment Ki67 is more important than Neo-Bioscore staging for predicting survival.
Source: link.springer.com/article/10.1007/s12672-023-00809-w
